Recursion Pharmaceuticals Inc (RXRX)
7.50
-0.08
(-0.99%)
USD |
NASDAQ |
Jun 28, 16:00
7.55
+0.05
(+0.67%)
After-Hours: 20:00
Recursion Pharmaceuticals Research and Development Expense (TTM): 262.11M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 262.11M |
| December 31, 2023 | 241.23M |
| September 30, 2023 | 215.72M |
| June 30, 2023 | 186.55M |
| March 31, 2023 | 169.93M |
| December 31, 2022 | 155.70M |
| September 30, 2022 | 160.01M |
| Date | Value |
|---|---|
| June 30, 2022 | 152.42M |
| March 31, 2022 | 143.60M |
| December 31, 2021 | 135.27M |
| September 30, 2021 | 107.68M |
| June 30, 2021 | 90.97M |
| March 31, 2021 | 74.59M |
| December 31, 2020 | 63.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
63.32M
Minimum
Dec 2020
262.11M
Maximum
Mar 2024
154.22M
Average
154.06M
Median
Research and Development Expense (TTM) Benchmarks
| Viking Therapeutics Inc | 76.90M |
| Tonix Pharmaceuticals Holding Corp | 73.01M |
| Actinium Pharmaceuticals Inc | 37.46M |
| Macrogenics Inc | 166.74M |
| Marinus Pharmaceuticals Inc | 95.57M |